When whale oil triglycerides were subjected to pancreatic lipase hydrolysis, eicosapentaenoic and docosahexaenoic acids were found mainly in the di- and triglyceride products, suggesting that they are in the 1,3-positions but resistant to the action of the lipase. Their presence in the 1,3-positions was confirmed. Their resistance to pancreatic lipase hydrolysis was demonstrated by analysis of the products of the enzyme action on: (a) a concentrate of highly unsaturated whale oil triglycerides; (b) the latter after randomization; and (c) synthetic 1,2-di-octadecenoyl-3-eicosapentaenoyl glycerol.Docosapentaenoic acid was also shown to be present in the 1,3-position of whale oil triglycerides but was not lipase resistant. It is postulated that the presence of a double bond near the carboxyl group exercises an inhibitory effect, or that the location of the double bonds in the resistant acids places their terminal methyl groups close to the carboxyl, producing a steric hindrance effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02533177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute pancreatitis (AP) is a life-threatening condition, with a higher mortality rate in men than women and in which estrogens might play a protective role. This study aimed to investigate sex-dependent differences in a mouse model of caerulein-induced AP. Thirty-six C57BL/6J mice (19 females and 17 males) were treated intraperitoneally with phosphate-buffered saline or caerulein, and sacrificed 12 hours, 2 days, or 7 days after the last injection.
View Article and Find Full Text PDFFGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis.
J Transl Med
January 2025
Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Background: Acute pancreatitis (AP) presents a significant clinical challenge with limited therapeutic options. The complex etiology and pathophysiology of AP emphasize the need for innovative treatments. This study explores mRNA-based therapies delivering fibroblast growth factor 21 (FGF21) and apolipoprotein A1 (APOA1), alone and in combination, for treating experimental AP.
View Article and Find Full Text PDFInsulin Therapy for Acute Pancreatitis in a Patient With Lipase Maturation Factor 1 Mutation: A Case Report.
J Community Hosp Intern Med Perspect
January 2025
Department of Medicine, Division of General Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Acute pancreatitis is a frequent cause of hospital admission, managed with intravenous (IV) fluids, analgesia, and oral feeding when tolerated. In patients with hypertriglyceridemia-induced pancreatitis, insulin and other therapies may be necessary for disease resolution. We present a case of a patient with severe acute pancreatitis and euglycemic diabetic ketoacidosis (DKA) with known lipase maturation factor 1 (LMF1) gene mutations, which can impact insulin efficacy on triglyceride metabolism through altered lipoprotein lipase activity, successfully treated with intravenous insulin.
View Article and Find Full Text PDFCoumarin Analogues as Promising Anti-Obesity Agents: In Silico Design, Synthesis, and In Vitro Pancreatic Lipase Inhibitory Activity.
Chem Biol Drug Des
January 2025
Laboratory of Natural Product Chemistry, Department of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS Pilani), Pilani, Rajasthan, India.
A set of coumarin-3-carboxamide analogues were designed, synthesized, and evaluated for their ability to impede pancreatic lipase (PL) activity. Out of all the analogues, 5dh and 5de demonstrated promising inhibitory activity against PL, as indicated by their respective IC values of 9.20 and 11.
View Article and Find Full Text PDFGenetic association of lipid-lowering drug target genes with pancreatic cancer: a Mendelian randomization study.
Sci Rep
January 2025
Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital, Shandong University, Jinan, 250012, China.
Article Synopsis
- Previous studies suggest dyslipidemia might increase the risk for pancreatic cancer (PC), and lipid-lowering drugs could help, but it's unclear if dyslipidemia directly causes PC.
- The Mendelian randomization study analyzed genetic data to explore the causal relationship between lipid traits and PC risk, finding no significant impact from lipid-lowering drugs.
- Genetic mimicry of the lipoprotein lipase (LPL) gene showed a potential association with PC risk, but this finding wasn't confirmed in follow-up analyses, suggesting dyslipidemia may not be a causal factor for PC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!